Apellis Pharmaceuticals, Inc. $APLS Stake Lessened by Duncan Williams Asset Management LLC

Duncan Williams Asset Management LLC decreased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 19.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,005 shares of the company’s stock after selling 4,120 shares during the quarter. Duncan Williams Asset Management LLC’s holdings in Apellis Pharmaceuticals were worth $294,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Assetmark Inc. boosted its position in Apellis Pharmaceuticals by 3,938.7% during the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock worth $27,000 after acquiring an additional 1,221 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after purchasing an additional 855 shares during the period. GF Fund Management CO. LTD. grew its position in Apellis Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after purchasing an additional 573 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Apellis Pharmaceuticals by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after purchasing an additional 655 shares in the last quarter. Finally, Legacy Capital Group California Inc. increased its stake in Apellis Pharmaceuticals by 32.8% in the 1st quarter. Legacy Capital Group California Inc. now owns 9,554 shares of the company’s stock valued at $209,000 after buying an additional 2,359 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Citigroup lifted their target price on shares of Apellis Pharmaceuticals from $41.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Royal Bank Of Canada lifted their price objective on Apellis Pharmaceuticals from $17.00 to $19.00 and gave the company a “sector perform” rating in a research report on Friday, August 1st. Wall Street Zen raised Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 2nd. Cantor Fitzgerald raised their price target on Apellis Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Finally, Morgan Stanley boosted their price target on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 2nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $33.29.

Insider Activity

In other news, CEO Cedric Francois sold 175,037 shares of the business’s stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $28.19, for a total value of $4,934,293.03. Following the completion of the sale, the chief executive officer directly owned 357,909 shares in the company, valued at approximately $10,089,454.71. The trade was a 32.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director A. Sinclair Dunlop sold 31,092 shares of the company’s stock in a transaction on Friday, September 19th. The stock was sold at an average price of $22.95, for a total transaction of $713,561.40. Following the sale, the director directly owned 68,908 shares of the company’s stock, valued at approximately $1,581,438.60. This represents a 31.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 430,919 shares of company stock valued at $10,656,945 over the last 90 days. 6.50% of the stock is currently owned by company insiders.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS opened at $24.36 on Tuesday. The stock has a market capitalization of $3.08 billion, a P/E ratio of -13.38 and a beta of 0.69. The business has a 50-day moving average of $25.02 and a two-hundred day moving average of $21.08. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $35.72. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.77 and a quick ratio of 3.16.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.11. The business had revenue of $171.39 million for the quarter, compared to the consensus estimate of $187.91 million. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.The firm’s revenue was down 10.6% compared to the same quarter last year. During the same period last year, the business earned ($0.30) EPS. On average, equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).